You can buy or sell BTAI and other stocks, options, ETFs, and crypto commission-free!
BioXcel Therapeutics, Inc. Common Stock, also called BioXcel Therapeutics, is a clinical stage biopharmaceutical company focuses on drug development. Read More The firm's two clinical development programs are BXCL501, a sublingual thin film formulation designed for acute treatment of agitation resulting from neurological and psychiatric disorders, and BXCL701, an immuno-oncology agent designed for treatment of a rare form of prostate cancer and for treatment of pancreatic cancer. The company was founded by Vimal D. Mehta on March 29, 2017 and is headquartered in New Haven, CT.
New Haven, Connecticut
52 Week High
52 Week Low
Simply Wall StMar 14
What Kind Of Shareholder Owns Most BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Stock?
A look at the shareholders of BioXcel Therapeutics, Inc. (NASDAQ:BTAI) can tell us which group is most powerful. Institutions often own shares in more established companies, while it’s not unusual to see insiders own a fair bit of smaller companies. We also tend to see lower insider ownership in companies that were previously publicly owned. With a market capitalization of US$146m, BioXcel Therapeutics is a small cap stock, so it might not be well known by many institutional investors. Taking a look at our...
Markets InsiderMar 8
This Day That Year: BioXcel Therapeutics
(RTTNews) - Shares of BioXcel Therapeutics Inc. (BTAI) are down nearly 47% from their all-time high of $14.79 recorded on July 10, 2018. It was on this day last year, i.e. on March 8, 2018, that BioXcel debuted on the NASDAQ Capital Market by setting a public offering at $11 per share. BioXcel Therapeutics is a clinical-stage biopharmaceutical company focused on drug development that utilizes novel artificial intelligence to identify the next wave of medicines across neuroscience and immuno-oncology. The...
Seeking AlphaMar 7
BioXcel Therapeutics, Inc. (BTAI) CEO Vimal Mehta on Q4 2018 Results - Earnings Call Transcript
BioXcel Therapeutics (NASDAQ:BTAI) Q4 2018 Earnings Conference Call March 7, 2019 8:30 AM ET Company Participants Carol Ruth - Founder and President, The Ruth Group Vimal Mehta - Founder, Chief Executive Officer, President, Secretary and Director Richard Steinhart - Chief Financial Officer Vincent O'Neill - Senior Vice President and Chief Medical Officer Frank Yocca - Chief Scientific Officer Conference Call Participants Scott Puckhaber - Barclays Keith Tapper - BMO Capital Markets Ram Selvaraju -...
-$0.39 per share
-$0.46 per share